Active, Not Recruiting
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
NCT05715216
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States